Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

Investors may react cautiously to news that Zydus Lifesciences Limited's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.938000
forwardPE 22.764942
debtToEquity 34.305000
earningsGrowth 0.381000
revenueGrowth 0.169000
grossMargins 0.715810
operatingMargins 0.212270
trailingEps 48.930000
forwardEps 0.000000

ZYDUSLIFE's current ratio of 1.938 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects ZYDUSLIFE's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
ZYDUSLIFE's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
ZYDUSLIFE's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that ZYDUSLIFE is expected to continue growing, with rising profits and sales contributing to its long-term success.
ZYDUSLIFE's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

ZYDUSLIFE's price projections have gradually declined, indicating growing uncertainty about the company's ability to meet previous targets. The downward trend reflects a more conservative view of ZYDUSLIFE's future.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


1 purchases of ZYDUSLIFE were executed, with market price of 951.4000244140625.There were no buy transactions during the period under consideration.More sells than buys at Zydus Lifesciences Limited's current price levels suggest a potential downside. If this selling trend persists, it could trigger further price declines, as increased selling often reflects investor pessimism about the stock's future prospects.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


The recent buy bias for Zydus Lifesciences Limited from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see Zydus Lifesciences Limited as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.